Skip to main content
. 2021 Dec 31;16(12):e0257972. doi: 10.1371/journal.pone.0257972

Fig 3. Binding and PD-L1/2 ligand blocking of HLX10.

Fig 3

(a) The binding of HLX10 antibody to either CHO-S or PD-1 transfected CHO-S cells was assessed by flow cytometry. The reference anti PD-1 antibody (Nivolumab) and anti-PD-L1 were used as the positive control and negative control (mAb control), respectively. Binding is determined as the mean fluorescent intensity (MFI) of staining. (b) The binding of HLX10 to PHA activated human T-cells was tested by flow cytometry. The ability of HLX10 to inhibit either PD-L1 (c) or PD-L2 (d) binding to cell surface PD-1 was assessed using flow cytometry. Anti-VEGF humanized antibody was used as the negative control (mAb control). All data points represent the means ± SD of triplicate. (e) PD-L1 blocking reporter assay. PDL-1 blocking activity is presented as increase in luciferase signal upon blocking by either HLX10 or Nivolumab reference antibody. Each datapoint represents mean ± SD of duplicate (n = 2).